The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.

Andreas Hochhaus

Honoraria - Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - ARIAD; Bristol-Myers Squibb; MSD; Novartis; Pfizer

Javier Pinilla-Ibarz

Consultant or Advisory Role - ARIAD

Honoraria - ARIAD

Dong-Wook Kim

Research Funding - ARIAD

Philipp D. Le Coutre

Honoraria - Bristol-Myers Squibb; Novartis

Ronald Paquette

Consultant or Advisory Role - ARIAD

Honoraria - ARIAD

Charles Chuah

Honoraria - Bristol-Myers Squibb; Novartis

Franck E. Nicolini

Consultant or Advisory Role - Novartis

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - Novartis

Jane Apperley

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Hanna Jean Khoury

No relevant relationships to disclose

Michele Baccarani

Consultant or Advisory Role - ARIAD

Honoraria - ARIAD; Novartis

Stephanie Lustgarten

Employment or Leadership Position - ARIAD

Stock Ownership - ARIAD

Victor M. Rivera

Employment or Leadership Position - ARIAD

Stock Ownership - ARIAD

Frank G. Haluska

Employment or Leadership Position - ARIAD

Consultant or Advisory Role - ARIAD (I); ARIAD

Stock Ownership - ARIAD

Honoraria - Lia Gore (I)

Research Funding - ARIAD

Francois Guilhot

Consultant or Advisory Role - ARIAD

Honoraria - ARIAD

Michael W.N. Deininger

Consultant or Advisory Role - AAIPharma; Bristol-Myers Squibb; Incyte; Novartis

Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis

Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Novartis; YM BioSciences

Timothy P. Hughes

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis

Neil P. Shah

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb

Research Funding - ARIAD; Bristol-Myers Squibb

Hagop M. Kantarjian

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Moshe Talpaz

Consultant or Advisory Role - ARIAD

Honoraria - ARIAD

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Jorge E. Cortes

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer; Teva

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva